search
Back to results

Allografts in Surgery of the Main Arteries

Primary Purpose

Critical Lower Limb Ischemia

Status
Recruiting
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Arterial bypass grafting
Sponsored by
Ryazan State Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Lower Limb Ischemia focused on measuring Critical Lower Limb Ischemia, atherosclerosis, peripheral arterial disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • males or females over 18 years of age;
  • critical lower limb ischemia due to atherosclerotic peripheral arterial disease.

Exclusion Criteria:

  • males or females less than 18 year of age;
  • decompensated concomitant pathology;
  • pregnancy or lactation.

Sites / Locations

  • Ryazan State Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Arterial bypass procedures using autologous venous graft

Arterial bypass procedures using allogeneic venous graft

Arterial bypass procedures using allogeneic arterial graft

Arterial bypass procedures using biologic bovine decellularized arterial graft

Arm Description

Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using autologous venous graft

Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic venous graft

Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic arterial graft

Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using biologic bovine decellularized arterial graft

Outcomes

Primary Outcome Measures

Number of Participants with lethal outcomes
The primary outcome measure is mortality rate

Secondary Outcome Measures

Number of Participants with Graft thrombosis
The secondary outcome measure is graft thrombosis
Myocardial infarction
The secondary outcome measure is myocardial infarction
Number of Participants with Acute coronary syndrome
The secondary outcome measure is acute coronary syndrome
Number of Participants with Stroke or transient ischemic attack
The secondary outcome measure is stroke or transient ischemic attack

Full Information

First Posted
July 4, 2022
Last Updated
July 8, 2022
Sponsor
Ryazan State Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05455138
Brief Title
Allografts in Surgery of the Main Arteries
Official Title
Allografts in Surgery of the Main Arteries
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
December 1, 2025 (Anticipated)
Study Completion Date
December 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ryazan State Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will examine the results of the use of biological materials (allogeneic arterial grafts, allogeneic venous graft, autologous vein, biological bovine decellularized graft) as a bypass grafts for reconstructive interventions in patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease in the short-term and long-term postoperative periods. Histological analysis of allogeneic grafts will be carried out at various time points of graft preservation with a Roswell Park Memorial Institute 1640 cell medicum with 400mcg/ml gentamicin and 20mcg/ml fluconazole at a temperature of +4C. The physical properties of allogeneic grafts from postmortem donors (tensile and tear strength) will be evaluated at various conservation time periods (1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks). Markers of endothelial dysfunction (IL-6, endothelin-1, 6-keto-prostaglandin F1alfa, eNOS) will be evaluated in patients with critical ischemia who undergo bypass procedures with arterial and venous allografts at various time points (before surgery, 7 days, 1 month, 3 months, 6 months, 1 year after).
Detailed Description
The study will include 200 patients of similar age, gender, and ethnicity, who will be divided into four groups: Group I: 50 patients who undergo arterial bypass procedures using autologous venous graft derived from great saphenous vein; Group II: 50 patients who undergo arterial bypass procedures using allogeneic venous grafts; Group III: 50 patients who undergo arterial bypass procedures using allogeneic arterial grafts; Group IV: 50 patients using biological bovine decellularized grafts. Patients will be monitored for 2 years: at inclusion, and 1, 3, 6, 12, 18, and 24 months after bypass procedures. The primary endpoint of the study will be mortality, i.e. death of the patient from any cause. Secondary endpoints of the study will be graft thrombosis and cardiovascular events such as myocardial infarction, acute coronary syndrome, transient ischemic attack, and stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Lower Limb Ischemia
Keywords
Critical Lower Limb Ischemia, atherosclerosis, peripheral arterial disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arterial bypass procedures using autologous venous graft
Arm Type
Experimental
Arm Description
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using autologous venous graft
Arm Title
Arterial bypass procedures using allogeneic venous graft
Arm Type
Experimental
Arm Description
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic venous graft
Arm Title
Arterial bypass procedures using allogeneic arterial graft
Arm Type
Experimental
Arm Description
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic arterial graft
Arm Title
Arterial bypass procedures using biologic bovine decellularized arterial graft
Arm Type
Experimental
Arm Description
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using biologic bovine decellularized arterial graft
Intervention Type
Procedure
Intervention Name(s)
Arterial bypass grafting
Intervention Description
Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
Primary Outcome Measure Information:
Title
Number of Participants with lethal outcomes
Description
The primary outcome measure is mortality rate
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Number of Participants with Graft thrombosis
Description
The secondary outcome measure is graft thrombosis
Time Frame
24 months
Title
Myocardial infarction
Description
The secondary outcome measure is myocardial infarction
Time Frame
1, 3, 6, 12, 18, and 24 months
Title
Number of Participants with Acute coronary syndrome
Description
The secondary outcome measure is acute coronary syndrome
Time Frame
24 months
Title
Number of Participants with Stroke or transient ischemic attack
Description
The secondary outcome measure is stroke or transient ischemic attack
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: males or females over 18 years of age; critical lower limb ischemia due to atherosclerotic peripheral arterial disease. Exclusion Criteria: males or females less than 18 year of age; decompensated concomitant pathology; pregnancy or lactation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Igor Suchkov, PhD, DMedSc
Phone
+7 (4912) 97-18-01
Email
suchkov_med@mail.ru
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Igor Suchkov, PhD, DMedSc
Organizational Affiliation
Ryazan State Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ryazan State Medical University
City
Ryazan
ZIP/Postal Code
390026
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vyacheslav В Karpov, PhD
Phone
+79105616427
Email
sdrr.s@yandex.ru

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Allografts in Surgery of the Main Arteries

We'll reach out to this number within 24 hrs